Mereo BioPharma Reports Q3 GAAP EPS of -$0.01, Cash on Hand at $48.7 Million

Mereo BioPharma Group reported Q3 GAAP EPS of -$0.01, in-line with expectations. As of September 30, 2022, the company had $48.7 million in cash and cash equivalents, down from $69.8 million at the end of 2021. Guidance remains unchanged, with the company expecting to use cash runway until mid-2024.